Interim Results of A Non-Interventional Post-Authorization Safety Study (pass) on the Long-Term Safety of Scig 10% Infusion Facilitated with Recombinant Human Hyaluronidase (rhuph20) in Patients with Primary Immunodeficiency Diseases (pidd) in Europe (Eu)